Skip to main content
HIThe HRT Index

About The HRT Index

Independent editorial coverage of online hormone therapy for women in perimenopause and menopause. Written for the reader who has been dismissed once and is now ready to take her own care seriously.

The HRT Index is an editorial publication. We exist because the conversation a midlife woman needs to have about hormone therapy — what her options are, what the trade-offs are, which clinicians actually know this material, what it costs — is not the conversation she is most likely to encounter at her primary-care appointment. The structural reason for that gap is well documented: most US medical schools dedicate fewer than two hours of instruction to menopause in four years, and the majority of practising OB/GYNs describe themselves as inadequately trained on the subject. The cultural reason is the long shadow of the 2002 Women's Health Initiative communication, whose initial framing has since been substantially re-evaluated by the major menopause societies but whose fingerprints remain on a generation of prescribing practice.

The HRT Index covers the new online HRT category — the cluster of telehealth practices that have emerged to fill that gap — with the editorial rigour that a serious women's-health publication should bring. We do not run sponsored rankings. We do not accept payment for inclusion. We label every page that has not undergone clinical review. We label every affiliate link. We publish our methodology, editorial standards, and medical review policy.

Who we are

The publication is produced by an editorial team of independent health-and-medicine researchers, writers, and editors. The team structure and the team's standing commitments are described on the editorial team page. The publication is in active build-out of a medical review board of NCMP-credentialed clinicians and OB/GYNs with menopause specialty experience; that board is described, honestly, on the medical reviewers page.

What we cover

The initial publication scope is online HRT providers serving women in the United States. The roadmap includes provider-specific reviews of the larger services in the category, deeper coverage of specific conditions in the perimenopause-to-postmenopause arc (vasomotor symptoms, sleep, mood, bone, cardiometabolic health, genitourinary syndrome of menopause), and adjacent women's-midlife topics where there is a real reader need and where we can hold ourselves to the same editorial standard.

We do not cover men's testosterone replacement. We do not cover fertility, contraception, or pregnancy. We do not offer medical, diagnostic, or treatment advice — we are a publication, not a clinical service. Reach us at our contact page.